Nearly 400 Cannabis Operators Have Filed With the DEA. The Window Closes June 22.

On the morning of Tuesday, April 29, 2026 — six days after Acting Attorney General Todd Blanche signed the final order rescheduling state-licensed medical cannabis to Schedule III — Trulieve Cannabis Corp. became the first major multistate operator to announce it had filed applications with the U.S. Drug Enforcement Administration to register its medical dispensary footprint under federal law. By that afternoon, the DEA's medical marijuana dispensary registration portal was live.

In the three weeks since, nearly 400 cannabis operators have filed applications. Verano Holdings, Green Thumb Industries, and Glass House Brands have each followed Trulieve's lead. The DEA's 60-day expedited filing window closes June 22, 2026. Operators who miss it lose the right to keep selling medical cannabis while their applications are processed.

The fees themselves are modest by industry standards — $794 per dispensary application, $3,699 per manufacturer, $1,850 per distributor, $296 for analytical labs. The cost of missing the window is not. For a state-licensed medical cannabis business that depends on continuity of operations, the choice between filing by June 22 and waiting it out is no choice at all. June 22 is, in practical terms, the new federal compliance deadline for the medical cannabis industry. (S1, S3)

The April 23 order — technically signed April 22 and published in the Federal Register April 28 — moved two specific categories of cannabis from Schedule I to Schedule III: FDA-approved cannabis products (already a small set, including Epidiolex) and state-licensed medical cannabis. Recreational and adult-use cannabis, which still generates the majority of revenue for most publicly traded multistate operators, remained Schedule I.

The legal mechanism was unusual. Rather than completing the standard notice-and-comment rulemaking process — which had stalled across two administrations — the Department of Justice invoked treaty compliance authority under 21 U.S.C. § 811(d)(1). The same provision was used in 2018 to schedule certain FDA-approved cannabidiol products. Treaty-compliance authority allows immediate effect; there is no public comment period. This is also why the order, while sweeping in scope, applies only to medical cannabis covered by state regulatory regimes. (S7, S8)

For state-licensed operators, the practical mechanics are spelled out in the DEA's expedited registration pathway. Within 60 days of publication, eligible medical cannabis businesses can file Form 510 for cultivation, manufacturing, distribution, or laboratory analysis; dispensary applications use a new dedicated portal at mmapplication.diversion.dea.gov. The state license itself serves as conclusive evidence of state-law authorization. Applications filed within the window are deemed approved unless the DEA actively notifies the applicant otherwise, and the agency has committed to processing those filings within six months. (S2, S4)

Trulieve, with more than 200 medical dispensaries across nine states, filed first. The company filed for 206 of its state-licensed medical retail locations on April 29 — likely the largest single multi-location DEA application package in cannabis history. Kim Rivers, Trulieve's CEO, called it a historic step forward for Trulieve and the patients it serves. (S5, S6)

Verano Holdings Corp., which operates roughly 130 dispensaries under the Zen Leaf, MÜV, and Verano brand families, filed in early May. Green Thumb Industries, parent of the RISE Dispensaries chain and one of the largest cultivation footprints in the industry, filed within the same window. Glass House Brands, smaller and more cultivation-weighted, filed for its California medical operations.

The early-filer dynamic matters because the DEA's six-month processing target applies only to applications received within the 60-day window. Operators that wait past June 22 will be processed eventually — but during that wait, they lose the deemed-approved-unless-notified status that allows them to continue operating under their state license. Practically, the difference between filing on June 21 and filing on June 23 is the difference between continuing to operate medical cannabis sales and stopping them.

The order also coincides with parallel DOJ moves on the broader question of recreational cannabis. The same day Blanche signed the medical rescheduling, the DOJ terminated the Biden-administration proceedings that had been considering broader rescheduling and set a new DEA administrative hearing for June 29, 2026 — one week after the medical filing window closes — to evaluate whether adult-use cannabis should follow. That second proceeding is what will determine whether the rest of the industry gets a similar pathway. (S4, S8)

Several legal observers have noted that the DEA registration form asks applicants to certify their prior business conduct. For operators whose state-licensed activity has been a federal Schedule I offense for years, certifying the activity creates a written record. In practice, the DOJ's cooperative-federalism framing in the order strongly suggests federal enforcement against state-compliant medical operators is not on the table. But the form remains, and operator legal counsel is reviewing the disclosures carefully.

The fees themselves underscore the modesty of the structural shift. A 206-dispensary operator like Trulieve faces an application bill of roughly $163,000 — meaningful, but a rounding error against Q1 2026 revenue of $287 million. The dollar cost of compliance is not the question. The question is whether operators can move their paperwork through legal review and into the DEA's system fast enough.

For operators, the rescheduling does three concrete things, in roughly ascending order of impact.

First, it relieves 280E. Section 280E of the Internal Revenue Code prohibits taxpayers trafficking in Schedule I or II controlled substances from deducting ordinary business expenses — wages, rent, marketing, depreciation. For cannabis operators, 280E has translated into effective federal tax rates that industry analysts have placed in the 70-to-75 percent range. Schedule III is not on the 280E list. The relief applies, for calendar-year taxpayers, from January 1, 2026 forward, but only to the medical side of the business. For an operator like Trulieve, which derives the majority of its revenue from medical operations, the cash impact lands immediately. The 35 percent adjusted EBITDA margin Trulieve reported for Q1 2026 reflects, in part, that the company was operating under the assumption medical rescheduling would land in time to claim deductions for the period.

Second, the rescheduling opens a narrow door to international medical cannabis trade. Schedule III drugs that are FDA-approved can, in principle, move across federal lines and across borders under existing controlled-substance treaty provisions. The state-licensed medical cannabis that Blanche's order covers is not FDA-approved as a finished product — but the door is, for the first time, conceptually open. Foley Hoag, in its post-order analysis, described the development as opening U.S. medical marijuana to global trade — for now. (S4)

Third, and most operationally significant, federal registration changes the relationship between operators and their financial counterparties. Cannabis companies have been blocked from major bank lending, default debit and credit card payments, and conventional insurance markets because their underlying activity was federally illegal. With state-licensed medical operations now registered Schedule III handlers, that conversation shifts. Treasury Department guidance, also issued in the week after the order, has begun to address how federal financial regulators should treat the medical side of cannabis businesses — though the recreational side remains a gray zone.

The shift is also bifurcating operator P&Ls in a way that finance teams have to start modeling immediately. A multistate operator with both medical and recreational revenue now runs two different federal tax regimes inside the same legal entity. Medical revenue is 280E-clean. Recreational revenue still carries the 70-percent-plus effective rate. Allocations between the two — particularly for expenses that touch both, like real estate, IT, and corporate overhead — become a material accounting question. Operators that pre-positioned for 280E relief by tightening their medical/rec cost allocations in 2025 are now better positioned than peers that did not.

For smaller, single-state medical-only operators — particularly in states without recreational programs, such as Florida, Pennsylvania, and Ohio — the picture is simpler. They get the full 280E relief on the full business. For them, the rescheduling represents perhaps the single largest improvement to cannabis P&L economics since the industry's commercial inception.

For the cannabis lender community, the rescheduling is mixed. The industry's approximately $6 billion in debt coming due by end of 2026 — concentrated in roughly five MSOs that collectively owe $3.4 billion — gets a different reception in refinancing conversations now that the medical side of the borrower's business is federally registered. Whether that translates into materially lower coupon rates on refinancing is still being tested in real time.

Recreational operators that do not also hold medical licenses are conspicuously left out. They face the same June 29 DEA hearing that the entire industry is watching, but for them it is the only path forward.

Industry voices have struck a careful tone — celebratory but cautious about what the order does not do.

Kim Rivers, CEO of Trulieve, has been the most public face of the early-filer cohort, framing registration as recognition of patient-serving work that operators have been doing in state systems for years. Her press statement called the moment a historic step forward for Trulieve and the patients it serves. (S5)

Legal counsel for cannabis operators has been more measured. The team at Foley Hoag, in its widely circulated client alert, emphasized that the order does not effect a broad rescheduling of cannabis. Marijuana that is neither contained in an FDA-approved drug product nor subject to a qualifying state-issued medical marijuana license, the firm wrote, remains a Schedule I controlled substance. Recreational cannabis, which continues to drive the majority of multistate operator revenue, falls outside the order's scope entirely. (S4)

Outside counsel for MSOs is meanwhile spending considerable hours on a less photogenic detail: the registration form itself asks applicants to certify their prior business activity. For an operator whose state-licensed activity has technically been a federal Schedule I offense, the form creates a written record of past conduct. The DOJ's cooperative-federalism framing strongly suggests federal enforcement against state-compliant operators is not contemplated. But the practical risk of memorializing the disclosure is being weighed.

Operator-facing accounting firms have begun retooling for the bifurcated tax regime. Specialty cannabis accounting practices have publicly described the post-April-23 environment as the most consequential tax shift cannabis has seen — but also the most operationally complex, requiring careful cost allocation between medical and recreational revenue.

Three concrete dates and one open question.

June 22, 2026 — the 60-day expedited-pathway window closes. Operators that file by this date can continue operating under their state licenses during the DEA's six-month review. Operators that miss it cannot. Expect a filing surge in the final week.

June 29, 2026 — the expedited DEA administrative hearing on broader rescheduling begins. This is the proceeding that will determine whether adult-use cannabis follows medical into Schedule III. Industry counsel is preparing testimony; the proceeding's scope and timeline are still being finalized. (S8)

December 22, 2026 — the end of the six-month DEA processing window for early filers. Operators that filed by June 22 should, by this date, have DEA registrations in hand or formal notice of issues. Operators that received a notice during the review period will need to have responded by this point. The volume of registrations the DEA can actually process in six months is, frankly, untested.

The open question is what happens to recreational. The June 29 hearing is the formal proceeding, but the political signal from the Acting Attorney General's office through the spring will matter as much as the hearing record. If the hearing concludes that adult-use cannabis warrants Schedule III treatment, the industry's federal compliance picture changes again, and another 60-day filing window will likely follow. If it does not — or if it produces a partial result, such as Schedule II for adult-use — the regulatory map remains the patchwork it is today.